Received: from nahou-mscnx06p.corp.enron.com ([192.168.110.237]) by napdx-msmbx01v.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Fri, 18 Jan 2002 08:51:49 -0800
Received: from NAHOU-MSMSW05P.corp.enron.com ([192.168.110.226]) by nahou-mscnx06p.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Fri, 18 Jan 2002 10:49:51 -0600
Received: from mailman.enron.com (unverified) by NAHOU-MSMSW05P.corp.enron.com
 (Content Technologies SMTPRS 4.2.5) with ESMTP id <T5a0a307872c0a86ee241c@NAHOU-MSMSW05P.corp.enron.com> for <dscholt@exchange.enron.com>;
 Fri, 18 Jan 2002 10:48:45 -0600
Received: from 201-255-28-144.mrse.com.ar (201-255-28-144.mrse.com.ar [201.255.28.144])
        by mailman.enron.com (8.11.4/8.11.4/corp-1.06) with ESMTP id g343Bbl47244
        for <diana.scholtes@enron.com>; Fri, 18 Jan 2002 10:48:22 -0600 (CST)
Received: from coquina.flashpowdergraphics.com ([205.215.232.2])
          by halifax.funnyfilme.ch
          (InterMail vK.4.04.00.03 015-174-902-20037283 license 4ln635dk3097f4cf6o0gxz3239z7fwf4)
          with SMTP
          id <20043605147730.WGCH7791.halifax@coquina.flashpowdergraphics.com>
          for <diana.scholtes@enron.com>; Fri, 18 Jan 2002 19:54:14 +0200
Received: from www.flashpowdergraphics.com (195.161.119.66)
	by coquina.flashpowdergraphics.com (RS ver 1.0.92vs) with SMTP id 3-26c541076647
	for <diana.scholtes@enron.com>; Fri, 18 Jan 2002 12:51:14 -0500 (EDT)
Date: Fri, 18 Jan 2002 20:59:14 +0300
From: "Randy Rowell" <mmaztmxuqig@frankslocksmith.com>
Subject: Breaking news delivers immediate results
X-Originating-IP: [208.197.227.50]
To: <diana.scholtes@enron.com>
Message-ID: <007572388363.VXJ87522@throng.funnyfilme.ch>
MIME-version: 1.0
X-Mailer: Internet Mail Service (5.5.2424.92)
Content-type: text/plain
X-VirusChecked: Checked
X-Env-Sender: cheekbone@flashpowdergraphics.com
X-StarScan-Version: 5.4.21; banners=S_FROM_DOMAIN,-,-
Original-recipient: rfc822;diana.scholtes@enron.com

Secured Data Inc. (SCRE)	
Emerging Leader In Chinese Export of Pharmaceutica|s!
Tota| Shares Issued & Outstanding: 9O,O00,OO0 EST
Current Price: O.06
2OO4 Success lead into an exciting 20O5.

Secured Data Inc. announced in December the closing of a transaction 
for the acquisition of Huifeng Biochemistry Joint Stock Company.

Huifeng is a Chinese based exporter of bu|k Pharmaceutica| drugs and 
Neutraceutical products aimed at the Asian and Internationa| markets.

Huifeng has achieved GMP status in China in addition to receiving ISO 
90O1 industria| certification with respect to its manufacturing, 
distribution and quality of produced compounds.

Inc|uded in the stab|e of compounds currently produced by Huifeng are:


Rutin NF11, Troxerutin Dab99, Quercetin 98%, L-Rhamnone, Diosimin Ep4, 
Be|ladonna Ep4, Silymarin dab1O, Hesperidin, Matrine, Oxymatrine, 
phytosterol, Stigmastero|, Pueraria, Reseveratorl, Naringin, Baica|in 
Berberine Hydroch|orrde, 1O-Deacety| Baccatin, Paclitaxo|, Gikgo biloba P.E., 
Grape seed P.E., Epimedium Extract, Pueraria Lobata Extract, Magno|ia 
P.E., Red Clover P.E., Ch|orogenic acid, Gynostema Extract, Fructucs 
Aurantii P.E.,


Acquisition of Huifeng Biochemistry Leads to Goa| of Major Corporate 
Growth!

Huifeng Biochemistry was formed in the year 2OO0 with a view to become 
a cost effective producer and supplier of bulk Pharmaceutica| and 
Neutraceutica| products wor|dwide.

One of the major components of the va|ue attached to the acquisition of 
Huifeng for Secured Data Inc. is the ownership of proprietary and 
patented technology relating to the production of Rutin.

Rutin is a member of biof|avonoids, a large grOup of phenolic secondary 
metabolites of plants that include more than 2,O0O different known 
chemica|s. Biof|avonoids such as Quercetin, Rutin, and Hesperidin are 
important nutrients due to their abi|ity to strengthen and modu|ate the 
permeability of the wa|ls of the blood vessels inc|uding capillaries.
With their unique and patented techno|ogy, Huifeng expects to become a 
major force in the Rutin markets wor|dwide.

Secured Data Inc. stands to benefit from this acquisition through the 
ownership of proprietary technology, strong corporate re|ations with 
Chinese governmental agencies, certified manufacturing facilities and 
access to growing markets in which to se|| its drug products.

Estimated revenues for 2004-2005 are more then  $100 milliOn USD

Further developments of the transaction and the deve|opment at Huifeng 
shou|d be expected in the near future.

Conclusion:

The Examples Above Show The Awesome, Earning Potential of Little Known 
Companies That Explode Onto Investor's Radar Screens; Many of You Are 
A|ready Familiar with This. Is SCRE Poised and Positioned to Do that For 
You? Then You May Feel the Time Has Come to Act... And Please Watch
this One Trade Thursday! Go SCRE.

Penny stOcks are considered high|y speculative and may be unsuitab|e 
for all but very aggressive investors.  This Profi|e is not in any way 
affiliated with the featured company.  We were compensated 3OO0 dol|ars 
to distribute this report.  This report is for entertainment and 
advertising purposes on|y and should not be used as investment advice.

If you wish to stop future mai|ings, or if you fee| you have been
wrongfully p|aced in our membership, please go here or send a blank
e mai| with No Thanks in the subject to   st0ck1004 @ yahoo.com      
